The findings and conclusions in this report are those of the auth

The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention. The authors state that they have no conflicts

of interest to declare. “
“Background. The National Travel Health Network and Centre (NaTHNaC) introduced a program of registration, training, standards, and audit for yellow fever vaccination centers (YFVCs) in England, Wales, and Northern Ireland (EWNI) in 2005. Prior to rolling out the program, NaTHNaC surveyed YFVCs in England. Objectives. To reassess the practice of YFVCs in 2009, 4 years after the institution learn more of the NaTHNaC program, to identify areas for ongoing support, and to assess the impact of the program. Methods. In 2009, all YFVCs in EWNI were asked to complete a questionnaire on type of practice, administration of travel vaccines, staff training, vaccine storage and patient record keeping, use of travel health information, evaluation of NaTHNaC yellow fever

(YF) training, and resource and training needs. Data were analyzed using Microsoft Excel® and STATA 9®. Results. The questionnaire was completed by 1,438 YFVCs (41.5% of 3,465 YFVCs). Most YFVCs were based in General Practice (87.4%). In nearly all YFVCs (97.0%), nurses advised travelers and administered YF vaccine. An annual median of 50 doses of YF vaccine was given by each YFVC. A total of 96.7% of nurses had received training in travel medicine, often through study days run by vaccine manufacturers. The internet was frequently used for information during travel consultations buy BMS-354825 (84.8%) and NaTHNaC’s on-line and telephone advice resources were highly rated. Following YF training, 95.8% of attendees expressed improved confidence regarding YF vaccination issues. There was excellent adherence to vaccination

standards: ≥94% correctly stored vaccines, recorded refrigerator temperatures, and maintained YF vaccination records. Conclusions. In the 4 years since institution of the NaTHNaC program Baf-A1 clinical trial for YFVCs, there has been improved adherence to basic standards of immunization practice and increased confidence of health professionals in YF vaccination. The NaTHNaC program could be a model for other national public health bodies, as they establish a program for YF centers. Yellow fever (YF) is a mosquito-borne flavivirus infection endemic in parts of Africa and South America. It is a viral hemorrhagic fever with a case-fatality rate of 20% to 50%.1 The World Health Organization (WHO) reports approximately 1,500 cases each year. It is likely that this is an underestimate, as many YF infections will go undetected or be attributed to other diseases.2 Vaccination of the international traveler against YF involves a complex decision-making process due to changes in the epidemiology of YF risk and rare, but potentially severe and life-threatening, adverse events following vaccination.

Leave a Reply

Your email address will not be published. Required fields are marked *


You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>